Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

However, the data showed that while obesity is a risk factor, so is a lack of fitness — even if you’re not clinically obese. The studies suggest that people of healthy, average weight with the lowest ...

Spokeo explored the negative impacts of smartphone usage on sleep and what people can do to get more restful downtime.

Earlier this month, the U.S. Food and Drug Administration proposed food companies use new, front-of-package labels highlighting the levels of fat, salt and added sugar in their products.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Working out how old your cat is in human years is not as straightforward as it is for dogs - but one vet has taken to social ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...